Corticosteroids in SARS-COV2 infection: certainties and uncertainties in clinical practice

References

• Fadaka AO, Sibuyi NRS, Adewale OB, et al. Understanding the epidemiology, pathophysiology, diagnosis and management of SARS-CoV-2. J Int Med Res. 2020;48(8):0300060520949077.
   PubMed Web of Science ®Google Scholar
• Shah VK, Firmal P, Alam A, et al. Overview of immune response during SARS-CoV-2 infection: lessons from the past. Front Immunol. 2020;11(1949). DOI:https://doi.org/10.3389/fimmu.2020.01949
   Google Scholar
• Tabary M, Khanmohammadi S, Araghi F, et al. Pathologic features of COVID-19: a concise review. Pathol Res Pract. 2020;216(9):153097.
   PubMed Web of Science ®Google Scholar
• Felsenstein S, Herbert JA, McNamara PS, et al. COVID-19: immunology and treatment options. Clin Immunol. 2020;215(108448):108448.
   PubMedGoogle Scholar
• Fu Y, Cheng Y, Wu Y. Understanding SARS-CoV-2-mediated inflammatory responses: from mechanisms to potential therapeutic tools. Virol Sin. 2020;35(3):266–271.
   PubMed Web of Science ®Google Scholar
• Yang M. Cell pyroptosis, a potential pathogenic mechanism of 2019-nCoV infection. (Ed.^(Eds) (2020)
   Google Scholar
• Wei Y, Lu Y, Xia L, et al. Analysis of 2019 novel coronavirus infection and clinical characteristics of outpatients: an epidemiological study from a fever clinic in Wuhan, China. J Med Virol. 2020;92(11):2758–2767.
   Web of Science ®Google Scholar
• Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically ill patients in the seattle region - case series. N Engl J Med. 2020;382(21):2012–2022.
   PubMed Web of Science ®Google Scholar
• Sinha P, Matthay MA, Calfee CS. Is a “cytokine storm” relevant to COVID-19? JAMA Intern Med. 2020;180(9):1152–1154.
   PubMed Web of Science ®Google Scholar
• Crisan-Dabija R, Pavel CA, Popa IV, et al. “A chain only as strong as its weakest link”: an up-to-date literature review on the bidirectional interaction of pulmonary fibrosis and COVID-19. J Proteome Res. 2020;19(11):4327–4338.
   PubMed Web of Science ®Google Scholar
• Nile SH, Nile A, Qiu J, et al. COVID-19: pathogenesis, cytokine storm and therapeutic potential of interferons. Cytokine Growth Factor Rev. 2020;53:66–70.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, Ch J. Cytokine Storm. N Engl J Med. 2020;383(23):2255–2273.
   PubMed Web of Science ®Google Scholar
• Mazzulli T, Farcas GA, Poutanen SM, et al. Severe acute respiratory syndrome-associated coronavirus in lung tissue. Emerg Infect Dis. 2004;10(1):20–24.
   PubMed Web of Science ®Google Scholar
• Samaddar A, Grover M, Nag VL. Pathophysiology and potential therapeutic candidates for COVID-19: a poorly understood arena. Front Pharmacol. 2020;11(1504).
   PubMedGoogle Scholar
• Kavsak PA, De Wit K, Worster A. Emerging key laboratory tests for patients with COVID-19. Clin Biochem. 2020;81(13):13–14.
   PubMedGoogle Scholar
• Mueller AA, Tamura T, Crowley CP. et al. Inflammatory biomarker trends predict respiratory decline in COVID-19 patients. Cell Rep Med. 2020;100144.
   Google Scholar
• Magro G. COVID-19: review on latest available drugs and therapies against SARS-CoV-2. Coagulation and inflammation cross-talking. Virus Res. 2020;286:198070.
   PubMed Web of Science ®Google Scholar
• Herold T, Jurinovic V, Arnreich C, et al., Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. J Allergy Clin Immunol. 146(1): 128–136 e124. 2020.
   PubMed Web of Science ®Google Scholar
• Azoulay E, Zafrani L, Mirouse A, et al. Clinical phenotypes of critically ill COVID-19 patients. Intensive Care Med. 2020;46(8):1651–1652.
   PubMed Web of Science ®Google Scholar
• Jeannet R, Daix T, Formento R, et al. Severe COVID-19 is associated with deep and sustained multifaceted cellular immunosuppression. Intensive Care Med. 2020;46(9):1769–1771.
   PubMed Web of Science ®Google Scholar
• Ale VA, Rijpstra TA, Belderbos HNA, et al. COVID-19-associated Pulmonary Aspergillosis. Am J Respir Crit Care Med. 2020;202(1):132–135.
   PubMed Web of Science ®Google Scholar
• Li H, Yang SG, Gu L, et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir Viruses. 2017;11(4):345–354.
   PubMed Web of Science ®Google Scholar
• Diaz E, Martin-Loeches I, Canadell L, et al. Corticosteroid therapy in patients with primary viral pneumonia due to pandemic (H1N1) 2009 influenza. J Infect. 2012;64(3):311–318.
   PubMed Web of Science ®Google Scholar
• Brun-Buisson C, Richard JC, Mercat A, et al. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med. 2011;183(9):1200–1206.
   PubMed Web of Science ®Google Scholar
• Martin-Loeches I, Lisboa T, Rhodes A, et al. Use of early corticosteroid therapy on ICU admission in patients affected by severe pandemic (H1N1)v influenza A infection. Intensive Care Med. 2011;37(2):272–283.
   PubMed Web of Science ®Google Scholar
• Kim Y-J, Guthrie KA, Waghmare A, et al. Respiratory syncytial virus in hematopoietic cell transplant recipients: factors determining progression to lower respiratory tract disease. J Infect Dis. 2014;209(8):1195–1204.
   PubMedGoogle Scholar
• Zaki AM, Van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367(19):1814–1820.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Balkhy HH, Hayden FG, et al. Middle East Respiratory Syndrome. N Engl J Med. 2017;376(6):584–594.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid therapy for critically ill patients with middle east respiratory syndrome. Am J Respir Crit Care Med. 2018;197(6):757–767.
   PubMed Web of Science ®Google Scholar
• Organization WH. SARS (Severe Acute Respiratory Syndrome). Geneva, Switzerland: World Health Organization (WHO). 2020.
   Google Scholar
• Hui DSC, Zumla A. Severe acute respiratory syndrome: historical, epidemiologic, and clinical features. Infect Dis Clin North Am. 2019;33(4):869–889.
   PubMed Web of Science ®Google Scholar
• Sung JJ, Wu A, Joynt GM, et al., Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak. Thorax. 59(5): 414–420. 2004.
   PubMed Web of Science ®Google Scholar
• Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus RNA concentrations in adult patients. J Clin Virol. 2004;31(4):304–309.
   PubMed Web of Science ®Google Scholar
• Yam LY-C, Lau AC-W, Lai FY-L, et al. Corticosteroid treatment of severe acute respiratory syndrome in Hong Kong. J Infect. 2007;54(1):28–39.
   PubMed Web of Science ®Google Scholar
• Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159–165.
   PubMed Web of Science ®Google Scholar
• Sun S, Liu D, Zhang H, et al. Effect of different doses and time-courses of corticosteroid treatment in patients with acute respiratory distress syndrome: a meta-analysis. Exp Ther Med. 2019;18(6):4637–4644.
   PubMed Web of Science ®Google Scholar
• Song Y, Zhang M, Yin L, et al. COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2). Int J Antimicrob Agents. 2020;56(2):106080.
   PubMed Web of Science ®Google Scholar
• Young MJ, Clyne CD, Chapman KE. Endocrine aspects of ACE2 regulation: RAAS, steroid hormones and SARS-CoV-2. J Endocrinol. 2020;247(2):R45–R62.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al., Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-infected pneumonia in Wuhan, China. JAMA. 323(11): 1061–1069. 2020.
   PubMed Web of Science ®Google Scholar
• Corral L, Bahamonde A, Arnaiz delas RF et al., GLUCOCOVID: a controlled trial of methylprednisolone in adults hospitalized with COVID-19 pneumonia. medRxiv. 2021 Apr;133(7-8):303-311
   Google Scholar
• Fadel R, Morrison AR, Vahia A, et al. Early short course corticosteroids in hospitalized patients with COVID-19. Clin Infect Dis. 2020;ciaa601.
   Google Scholar
• Investigators TWCftR-C. Effect of hydrocortisone on mortality and organ support in patients with severe COVID-19: the REMAP-CAP COVID-19 corticosteroid domain randomized clinical trial. JAMA. 2020;324(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Villar J, Ferrando C, Martínez D, et al., Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 8(3): 267–276. 2020.
   PubMed Web of Science ®Google Scholar
• Health NIo. COVID-19 treatment guidelines panel. coronavirus disease 2019 (COVID-19) treatment guidelines. Health, NIo (Ed.^(Eds) (2020).
   Google Scholar
• Dexamethasone in Hospitalized Patients with Covid-19. Preliminary report. N Engl J Med. 2021 Feb 25;384(8):693-704
   Google Scholar
• Tomazini BM, Maia IS, Cavalcanti AB, et al. Effect of dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: the CoDEX randomized clinical trial. JAMA. 2020;324(13):1307–1316.
   PubMed Web of Science ®Google Scholar
• Zhao JP, Hu Y, Du RH, et al. [Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia]. Zhonghua Jie He He Hu Xi Za Zhi. 2020;43:E007.
   PubMedGoogle Scholar
• Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020;395(10225):683–684.
   PubMed Web of Science ®Google Scholar
• Mongardon N, Piagnerelli M, Grimaldi D, et al. Impact of late administration of corticosteroids in COVID-19 ARDS. Intensive Care Med. 2021;47(1):110–112.
   PubMed Web of Science ®Google Scholar
• Li Q, Li W, Jin Y, et al. Efficacy evaluation of early, low-dose, short-term corticosteroids in adults hospitalized with non-severe COVID-19 pneumonia: a retrospective cohort study. Infect Dis Ther. 2021 Feb 25;384(8):693-704
   Web of Science ®Google Scholar
• Xu K, Chen Y, Yuan J, et al. Factors associated with prolonged viral RNA shedding in patients with coronavirus disease 2019 (COVID-19). Clin Infect Dis. 2020;71(15):799–806.
   PubMed Web of Science ®Google Scholar
• Li T-Z, Cao Z-H, Chen Y, et al. Duration of SARS-CoV-2 RNA shedding and factors associated with prolonged viral shedding in patients with COVID-19. J Med Virol. 2020;93(1):506–512.
   Web of Science ®Google Scholar
• Salton F, Confalonieri P, Meduri GU, et al. Prolonged low-dose methylprednisolone in patients with severe COVID-19 pneumonia. Open Forum Infect Dis. 2020;7(10):ofaa421.
   PubMed Web of Science ®Google Scholar
• Tlayjeh H, Mhish OH, Enani MA, et al. Association of corticosteroids use and outcomes in COVID-19 patients: a systematic review and meta-analysis. J Infect Public Health. 2020;13(11):1652–1663.
   PubMed Web of Science ®Google Scholar
• Waljee AK, Rogers MAM, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357(j1415).
   Google Scholar
• Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J. 2020;2001009.
   Google Scholar
• Trials C. Adaptive COVID-19 treatment trial 4 (ACTT-4). (Ed.^(Eds) (2020)
   Google Scholar